Wasser Clear

Quick links to important sections

Wasser Clear

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Wasser Clear

Wasser Clear is an over-the-counter (OTC) pharmaceutical product whose identity is defined by its active ingredient, Tetryzoline (chemically known as Tetrahydrozoline hydrochloride). It is a synthetic compound typically formulated as a clear aqueous solution for topical administration.

Quick Facts

Property Description
Active ingredient Tetryzoline (Tetrahydrozoline hydrochloride)
Form Ophthalmic solution (Eye drops)
Pharmacological class Alpha-adrenergic agonist / Sympathomimetic amine
Common use Relief of local redness and swelling
Origin Synthetic (Imidazoline derivative)

What is the Chemical and Pharmacological Identity of Wasser Clear?

Wasser Clear belongs to the sympathomimetic amine pharmacological group, functioning specifically as an alpha-adrenergic agonist. The Tetryzoline molecule, an Imidazoline derivative, constitutes the medicine's core component. This classification identifies the substance as an agent designed to act on the body’s sympathetic nervous system receptors. This preparation is predominantly a monotherapy, relying solely on the action of this single compound. The formulation's established role is as an ophthalmic solution (eye drops) for direct application, which is utilized for reducing superficial congestion in the conjunctiva.

What Type of Medicine is Tetryzoline and What is its General Purpose?

Tetryzoline is broadly defined as a decongestant whose function is to temporarily reduce localized vascular swelling. Tetrahydrozoline is used to relieve redness caused by minor eye irritations. This identifies the medicine's general purpose as providing symptomatic relief for temporary, minor irritation affecting the capillaries of the eye or nasal mucosa. The drug's therapeutic benefit relies on its primary physiological action of localized vasoconstriction—the narrowing of the superficial blood vessels. The effect helps ease the visual sign of eye redness by physically reducing the volume of blood causing the swelling.

Regulatory References

  1. sympathomimetic amine classification
  2. alpha-adrenergic agonist classification
  3. monotherapy
  4. decongestant
  5. red eye
  6. eye redness
  7. Physiological action

What side effects are possible with Wasser Clear?

Possible Side Effects and Safety Information

This section describes the officially documented safety characteristics and reported adverse reactions for ophthalmic Tetrahydrozoline, the active ingredient in Wasser Clear, as classified by government regulatory sources.


Classification of Official Adverse Reactions

Adverse reactions primarily affect the Eye and, due to potential systemic absorption, the Central Nervous and Cardiovascular Systems.

System Organ Class (SOC) Documented Adverse Reactions
Eye Disorders Mild burning or stinging sensation, eye irritation, blurred vision, mydriasis (dilated pupils), ocular hyperaemia (rebound congestion), increased tearing.
Nervous System Disorders Headache, drowsiness, nervousness.
Cardiac Disorders Tachycardia (fast heart rate), palpitation.
Vascular Disorders Hypertension (high blood pressure), pallor.

Local effects such as stinging or mild burning are commonly reported and generally transient. Other effects, including mydriasis and blurred vision, are also documented. Systemic effects like headache, tachycardia, and hypertension are considered Frequency Not Known and are associated with sympathomimetic action.


Safety Considerations for Specific Populations and Overuse

Accidental Ingestion in Children: Government health authorities warn of a severe risk of serious adverse events following accidental ingestion, particularly in young children. Reported symptoms include coma, decreased heart rate (bradycardia), decreased breathing (respiratory depression), and sedation, necessitating immediate supportive care.

Duration-Related Risk: The overuse or prolonged frequent use of the solution may lead to reactive hyperaemia (rebound congestion), an increase in eye redness that can exceed the initial severity.

Safety Restrictions: Caution is advised in patients with pre-existing conditions sensitive to sympathomimetic effects, such as narrow-angle glaucoma, severe cardiovascular disease, uncontrolled hypertension, diabetes mellitus, and hyperthyroidism. Tetryzoline is also restricted for use in individuals receiving monoamine oxidase inhibitors (MAOIs) or within 14 days of stopping such treatment.

Overdose and Emergency Response

The official regulatory profile for Wasser Clear (Tetryzoline) overdose is defined by the potential for serious systemic toxicity following accidental oral ingestion of the ophthalmic solution.

Documented Manifestations and Severe Outcomes

Systemic absorption is documented to affect the Central Nervous System (CNS), Cardiovascular, and Respiratory systems. Manifestations include signs of CNS depression such as somnolence, lethargy, and coma, along with significant changes in vital signs. These may involve bradycardia (slow heart rate), initial hypertension followed by hypotension (low blood pressure), miosis (pinpoint pupils), and decreased respiration leading to respiratory depression. Regulatory sources indicate overdose may result in life-threatening adverse events, including cardiovascular collapse.

Mandatory Emergency Action

Due to the risk of severe complications, all regulatory labeling mandates immediate medical attention. If a known or suspected overdose occurs, it is required to seek help right away and contact a Poison Control Center. Urgent medical intervention is necessary if the affected individual collapses, has a seizure, or cannot be awakened.

Population Risk and Management

Regulatory warnings emphasize the extreme risk to children 5 years of age and younger. Ingesting a small volume (1 to 2 mL, or several drops) is documented to be toxic, potentially causing coma and apnea. Management is symptomatic and supportive, as no specific antidote is known. This includes close hospital monitoring of vital signs and may involve procedures such as ECG and airway support.

Therapeutic Uses of Wasser Clear

What Wasser Clear Treats: Main Uses and Benefits

Wasser Clear (Tetryzoline ophthalmic solution) is commonly used to help with symptoms associated with minor eye irritations, offering supportive symptomatic management for non-serious, temporary conditions. Ophthalmic tetrahydrozoline is considered relevant for easing discomfort and redness caused by seasonal factors and situational irritants.

Therapeutic Support for Ocular Symptoms

The medication may assist with managing primary symptom clusters, including visible ocular redness (hyperemia), a bloodshot appearance, and minor sensory discomfort such as a burning or stinging sensation. These issues often arise in conditions characterized by periods of heightened symptoms due to factors like dust, wind, smog, or exposure to chlorinated water.

The overall therapeutic support is that it contributes to improved day-to-day comfort during symptomatic periods, providing supportive relief when symptoms become temporarily overwhelming. It assists with maintaining functional stability by addressing the most noticeable physical manifestations.


Quick Fact: The product is commonly used for Temporary Ocular Redness and Minor Burning.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

The eligibility for using Wasser Clear (Tetryzoline ophthalmic solution) is strictly defined by regulatory documents, which establish the populations permitted, restricted, or prohibited from self-medication.

Category Official Regulatory Status
Populations for Self-Use Adults and Children aged 6 years and older are permitted for use under labeled conditions.
Absolute Contraindications Narrow-Angle Glaucoma and known Hypersensitivity to tetrahydrozoline or any ingredient are grounds for absolute prohibition.
Pediatric Restrictions Use in children under 6 years of age requires consultation with a doctor. Some regulators explicitly contraindicate use in children under 2 years of age.
Conditional Use Individuals with pre-existing systemic conditions, including Heart Disease, High Blood Pressure, Diabetes, or Hyperthyroidism, must ask a doctor before use.
Physiological Status Pregnant or breastfeeding individuals are restricted and must ask a health professional before use as a labeled precaution.

These constraints ensure that individuals with systemic or ocular conditions that may be sensitive to the drug's action are directed away from self-treatment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Tetryzoline ophthalmic solution focuses on documented pharmacodynamic interactions resulting from the systemic absorption of the alpha-adrenergic agonist active ingredient.


Contraindicated Combinations and Timing Rules

Co-administration of Tetryzoline with Monoamine Oxidase Inhibitors (MAOIs) is formally classified as a contraindicated combination. Due to the systemic sympathomimetic action of Tetryzoline, its use is prohibited concurrently with MAOIs. Furthermore, the official labeling mandates a timing separation rule: the product must not be administered within 14 days of discontinuing treatment with any MAOI. This restriction is based on the potential for a severe additive sympathomimetic effect.


Other Pharmacodynamic Interactions

Other interactions listed in regulatory documents are classified as requiring caution. These involve medicinal products that may create additive systemic effects or counteract Tetryzoline's action. Caution is specified for use with other sympathomimetic drugs due to the risk of increased cardiovascular stimulation.

Additionally, the regulatory profile advises caution with certain anti-hypertensive agents, including Digitalis, Beta-adrenergic blockers, Reserpine, Methyldopa, and Guanethidine. Tetryzoline’s systemic effect may interfere with the blood pressure-lowering action of these medicines. The use of Tetryzoline with halogenated anaesthetic agents, such as Halothane, Enflurane, and Isoflurane, is also listed with caution, as this combination may provoke or worsen ventricular arrhythmias.

The official regulatory documents do not specify any interaction with food, alcohol, herbal products, supplements, or any drug interactions mediated by Cytochrome P450 enzymes or drug transporters.

Mechanism of Action

The active ingredient operates exclusively on the pharmacodynamic mechanisms that govern localized vascular diameter and blood flow. Its overall pharmacodynamic consequence is derived from the following specific molecular and physiological processes.


Targeting alpha1 Adrenergic Receptors and Vascular Tone

The mechanism of action initiates with the potent activation, or agonism, of the alpha-1 (alpha1) adrenergic receptors found on the post-synaptic membranes of the vascular smooth muscle cells in the eye's superficial blood vessels. This interaction triggers a rapid internal calcium cascade, directly leading to the contraction of the smooth muscle. This action locally modulates the sympathetic autonomic pathway, leading to a physical decrease in blood vessel diameter (vasoconstriction).


Localized Physiologic Cascade and Flow Restriction

The subsequent physical vasoconstriction is the core physiological change. By physically reducing the diameter of the local arterioles and capillaries, the mechanism immediately restricts the local volume and flow of blood within the affected tissue. This reduction in blood volume decreases the transudation of fluid from the vessels. This targeted flow restriction limits the extent of vascular engorgement and localized fluid accumulation.


Mechanism Constraints: Receptor Desensitization and Withdrawal Effects

The vasoconstrictive mechanism is subject to specific constraints. Prolonged or frequent application can lead to receptor desensitization (tachyphylaxis), where the alpha1 receptors become progressively less responsive to the agonist, weakening the response. Furthermore, chronic receptor stimulation can induce a compensatory biological mechanism, which results in vasodilation upon withdrawal of the agonist. This physiological change demonstrates the mechanistic constraint of sustained alpha1 agonism.

Dosage and Administration Information

How to Use Wasser Clear

Wasser Clear is officially designated for use exclusively as a solvent or diluent for other medicinal products that require parenteral administration (such as intravenous, intramuscular, or subcutaneous injection). It must never be administered alone, and its usage is strictly defined by the instructions for the co-administered drug.

Official Administration Guidelines

Instruction Area Requirement
Route of Administration Determined by the medicinal product (additive) being dissolved or diluted.
Dosing Schedule Volume and administration rate are entirely dependent upon the specific instructions for the additive medicinal product.
Preparation Requirements Used for dilution or dissolution; should be mixed with the additive and administered immediately before use.
Age-Group Rules Dosage for pediatric and other populations must strictly follow the instructions given for the additive medicinal product.

Procedural Structure

Administration must follow a specific sequence as mandated in official guidelines:

  1. Inspection: The solution must be visually inspected and should only be used if it is clear, colorless, and free from visible particles; the container must be undamaged.
  2. Dilution: Utilize the solution for the reconstitution or dilution of the specified co-administered parenteral medicinal product according to its labeled instructions.
  3. Timing: The final prepared solution must be administered immediately after preparation to ensure stability and sterility.
  4. Disposal: Containers are intended for single use only; any unused portion must be immediately discarded.

These instructions define the standardized approach for the correct preparation and administration of parenteral medicines where this solvent is required. The entire protocol of use is structurally dependent upon the official labeling of the active drug it is intended to dilute.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase III Clinical Trials

Clinical trials are a critical step in exploring any new treatment. Studies explored the drug's activity, which involved modulating specific receptors, in relation to reported symptom changes. Key Phase III trials provided substantial data for evaluation.

Efficacy and Quality of Life Studies

Initial Phase III studies investigated whether it could be associated with an improvement in overall quality of life in participants reporting moderate to severe symptoms. Research explored the speed of reported symptom changes, focusing on daily activity levels and self-reported well-being scores.

The research evaluated this treatment’s impact on various metrics, including reported symptom severity, and examined reported changes in pain following administration.

Tolerability and Long-Term Outcomes

One approach examined the drug's tolerability profile over a 6-month period. Research examined whether the drug could be associated with sustained reported changes in symptoms and collected data on adverse events.

A finding was that studies reported the drug’s tolerability profile across different populations, including the types and frequency of reported side effects. Furthermore, studies have included participants with chronic conditions, allowing for the evaluation of its use in these populations.

Combination Therapy Research

Some post-marketing research and smaller clinical trials have explored the drug’s use in combination with established therapies.

Clinical trials explored the drug’s reported outcomes when administered alongside standard care treatments. The results of these trials focused on changes in symptom scores over a 12-week period, which explored reported changes in patient outcomes associated with the combination.

Key Studies & References Clinical study reports—a systematic review with thematic synthesis part 2 (Focus on Benefits and Harms)

Frequently Asked Questions (FAQ)

Common questions about Wasser Clear (FAQ)

Q: Is it possible for Wasser Clear to affect my sleep?

Official product information notes that systemic effects, although usually uncommon, can include drowsiness and nervousness. These nervous system responses may potentially impact rest or sleep patterns.

Q: Can older adults use Wasser Clear safely?

The regulatory profile places restrictions on use for individuals with certain pre-existing systemic conditions. This includes older adults who may have conditions like high blood pressure, diabetes, or heart disease. In these situations, official labeling suggests that a health professional should be consulted before use.

Q: Is Wasser Clear considered safe for long-term use?

Prolonged or frequent use of the solution is associated with a risk known as rebound congestion or reactive hyperaemia. This is a documented side effect where the eye redness may increase or worsen after stopping use. Official documentation mentions this potential effect of overuse.

Q: Is it true that Wasser Clear can make you feel dizzy?

The official safety information documents side effects related to the nervous system, such as drowsiness and headache. Although dizziness is not specifically named in the product information, these related effects may occur due to systemic absorption of the active ingredient.

Q: What happens if I stop taking Wasser Clear suddenly?

The mechanism of action involves the narrowing of blood vessels (vasoconstriction). Upon withdrawal of the medicine, this action can lead to a compensatory biological change known as vasodilation, where blood vessels may widen. This mechanistic constraint is what causes the potential for rebound congestion.

Q: Is there a link between Wasser Clear and changes in mood?

Official product information describes nervousness as a potential adverse reaction affecting the central nervous system. The regulatory profile focuses on this specific effect rather than broader changes in mood.

Q: Can I drive or operate machinery while taking Wasser Clear?

Official safety documents list certain side effects that may temporarily affect your ability to perform tasks. These include visual disturbances, such as blurred vision, and systemic effects like drowsiness. The regulatory profile notes that caution is advised based on how the product's documented effects are experienced.

Q: What is the shelf life of Wasser Clear?

The official instructions regarding the product's stability focus on its appearance. Regulatory information states that the solution should be immediately discarded if it changes color, becomes cloudy, or if any visible particles are present. These instructions help ensure the medicine is used only while its physical appearance and integrity are maintained.

Q: What are the serious but rare side effects of Wasser Clear?

Official warnings highlight the risk of severe adverse events following accidental ingestion, especially in young children, which can include coma and decreased heart rate. Systemic effects such as hypertension (high blood pressure) and tachycardia (fast heart rate) are also documented, with their frequency generally classified as not known in the regulatory information.

Q: Can I take other prescription medications with Wasser Clear?

The regulatory profile specifies certain classes of prescription medicines that interact with the active ingredient. These include MAOIs, which are contraindicated, and medications like certain anti-hypertensives, where caution is specified due to the potential for interference.

Q: What does 'contraindication' mean for Wasser Clear?

In official medical documents, a contraindication refers to a specific condition or circumstance where the medicine should not be used because the risks outweigh the potential benefit. For this medicine, the absolute contraindications listed include having narrow-angle glaucoma or a known hypersensitivity to any of its components.

Q: If I have allergies, can I still take Wasser Clear?

Official eligibility rules specify that a known Hypersensitivity (a severe allergic reaction) to the active ingredient or other components of the solution is an absolute contraindication, meaning the medicine is prohibited from use. Hypersensitivity is an absolute contraindication, so users should be aware of the specific ingredients listed in the product label.

Q: Are the side effects of Wasser Clear permanent?

Official documentation describes local adverse reactions, such as mild burning or stinging, as being generally transient, meaning they are temporary. Furthermore, the duration-related risk of rebound congestion is linked to the overuse of the solution, suggesting that the effect is reversible upon discontinuation.

Q: How long does it typically take before someone feels a difference from Wasser Clear?

The active ingredient works by localized vasoconstriction, which is the narrowing of superficial blood vessels. Regulatory reference sources indicate that the duration of this effect typically lasts for approximately 2 to 3 hours. This duration is the time the physiological change is expected to be present.

Q: Is there a generic version of Wasser Clear available?

The active ingredient in the solution is Tetryzoline, and regulatory databases list this ingredient under numerous product names. This indicates that the active component is widely available in many formulations.

Q: Are there any specific activities or foods to avoid while on Wasser Clear?

Official regulatory documents do not specify any required food restrictions while using the solution. However, due to documented side effects like blurred vision and drowsiness, caution is noted regarding activities that require clear sight and full alertness.

Q: What should I do if I notice a common side effect from Wasser Clear?

Official instructions state that stopping use and consulting a doctor is advised if certain specific symptoms occur. These include any signs of eye pain, experiencing changes in vision, or if the redness or irritation persists for more than 72 hours after beginning the treatment.

Q: Can people with kidney issues take Wasser Clear?

The official eligibility profile lists several pre-existing systemic conditions that require consultation with a health professional before use. While kidney issues are not explicitly named in this list, the regulatory guidance indicates that a health professional should be consulted before use for individuals with chronic systemic conditions.

Q: How long after starting Wasser Clear should I wait to see maximum results?

The time it takes for the concentration of the active ingredient in the body to drop by half, known as the mean serum half-life, is approximately 6 hours following therapeutic application. This pharmacological data helps illustrate how the body processes the solution.

Q: Does the time of day matter when taking Wasser Clear?

Official information indicates that the drops are intended for application in the affected eye(s) up to 4 times daily. The product information does not specify that the application must occur at a particular time of day.

Q: How frequently is Wasser Clear typically taken?

Official instructions indicate that the product is typically applied in the affected eye(s) up to 4 times daily. This frequency is based on the therapeutic application of the ophthalmic solution.

Q: Is there any research on Wasser Clear for pediatric use?

The eligibility profile addresses the use of the medicine in children by placing specific restrictions on the pediatric population. Official documents state that consultation with a doctor is advised for use in children under the age of 6.

Q: Is it normal to feel a bit nauseous when first starting Wasser Clear?

Official safety documents do not list nausea and vomiting as expected common side effects of therapeutic use. However, these effects have been documented in regulatory sources in cases involving high systemic absorption or accidental overdose.

Q: Is Wasser Clear a controlled substance?

Official regulatory classifications indicate that the active ingredient, Tetryzoline, in ophthalmic solution form is classified as Not a controlled drug. This classification is made according to the Controlled Substances Act (CSA).

Q: Does coffee or caffeine consumption affect Wasser Clear?

Interaction databases reviewed by regulatory bodies note a potential for increased risk or severity of adverse effects when the active ingredient is combined with caffeine. This is related to the compounded sympathomimetic action of both substances on the body.

Q: How long does Wasser Clear stay in the system after the last dose?

Pharmacological data indicates how long the active ingredient remains detectable in the system. Following therapeutic use, the substance has been detected in blood serum and urine for up to 12 hours after the final dose.

Q: What regulatory bodies have approved Wasser Clear for use?

The active ingredient is reviewed and regulated by major governmental drug authorities worldwide. These official regulatory bodies include the FDA (U.S.), the EMA (Europe), and the MHRA (U.K.). Product information and safety data are publicly available through their respective databases.

Q: Are there different strengths available for Wasser Clear?

Official regulatory listings for the ophthalmic solution primarily document a specific concentration of the active ingredient. The most common strength listed is a 0.05% concentration of Tetryzoline.

How should Wasser Clear be stored and disposed of?

How to Store and Dispose of Wasser Clear?

The official storage and disposal profile for Wasser Clear (Tetryzoline ophthalmic solution) is governed by specific regulatory requirements to ensure product stability and public safety.

Official Storage Requirements

Condition Regulatory Rule
Temperature Store at controlled room temperature, typically between 15 C to 30 C (59 F to 86 F), and away from excess heat.
Prohibited Areas Do not freeze the solution. Keep away from moisture and avoid storage in high-humidity areas, such as a bathroom.
Container Rule Must be kept in the original container with the cap tightly closed when not in use.
Child Safety Mandatory: Must be stored out of the sight and reach of children due to the risk of serious adverse effects from accidental ingestion.

Stability and Disposal

Stability is tied to the solution’s physical appearance; the medicine must be discarded if it changes color, appears cloudy, or contains particles. For disposal, unused or expired solution must be disposed of properly, preferably through a community drug take-back program. It must not be flushed down a toilet or poured into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Wasser Clear found in:

A-Z Index: